Royal Bank of Canada Lowers Oncolytics Biotech (NASDAQ:ONCY) Price Target to $5.00

Oncolytics Biotech (NASDAQ:ONCY - Get Free Report) had its price objective decreased by equities researchers at Royal Bank of Canada from $6.00 to $5.00 in a research note issued on Monday,Benzinga reports. The brokerage presently has an "outperform" rating on the stock.

Several other brokerages have also recently weighed in on ONCY. Raymond James upgraded Oncolytics Biotech to a "moderate buy" rating in a research report on Thursday, November 14th. Leede Financial cut Oncolytics Biotech from a "strong-buy" rating to a "moderate buy" rating in a research report on Wednesday, November 13th. Finally, HC Wainwright reiterated a "buy" rating and set a $5.00 price target on shares of Oncolytics Biotech in a research report on Monday, February 3rd. Three equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Oncolytics Biotech currently has an average rating of "Buy" and an average target price of $4.00.

Oncolytics Biotech Stock Up 0.3 %

Oncolytics Biotech stock traded up $0.00 during midday trading on Monday, reaching $0.63. The stock had a trading volume of 118,147 shares, compared to its average volume of 1,288,895. Oncolytics Biotech has a 12 month low of $0.58 and a 12 month high of $1.53. The firm's 50-day moving average price is $0.76 and its 200 day moving average price is $0.92. The firm has a market capitalization of $53.44 million, a PE ratio of -2.31 and a beta of 1.18.

Remove Ads

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. International Assets Investment Management LLC grew its holdings in shares of Oncolytics Biotech by 15.0% during the fourth quarter. International Assets Investment Management LLC now owns 200,400 shares of the company's stock worth $186,000 after purchasing an additional 26,069 shares in the last quarter. Vantage Point Financial LLC purchased a new position in shares of Oncolytics Biotech during the fourth quarter worth about $27,000. Geode Capital Management LLC grew its holdings in shares of Oncolytics Biotech by 59.6% during the fourth quarter. Geode Capital Management LLC now owns 66,939 shares of the company's stock worth $61,000 after purchasing an additional 24,997 shares in the last quarter. National Bank of Canada FI grew its holdings in shares of Oncolytics Biotech by 199.6% during the fourth quarter. National Bank of Canada FI now owns 64,479 shares of the company's stock worth $60,000 after purchasing an additional 42,955 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in Oncolytics Biotech in the fourth quarter worth approximately $90,000. Hedge funds and other institutional investors own 6.82% of the company's stock.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.